 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.22.27
- Cathepsin S.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Similar to cathepsin L, but with much less activity on Z-Phe-Arg-|-NHMec, and more activity on the Z-Val-Val-Arg-|-Xaa compound.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
proteolysis
|
1 term
|
 |
|
Biochemical function
|
cysteine-type peptidase activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Acta Crystallogr D Biol Crystallogr
58:451-455
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of a Cys25-->Ser mutant of human cathepsin S.
|
|
J.P.Turkenburg,
M.B.Lamers,
A.M.Brzozowski,
L.M.Wright,
R.E.Hubbard,
S.L.Sturt,
D.H.Williams.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cathepsin S (EC 3.4.22.27), a cysteine proteinase of the papain superfamily,
plays a critical role in the generation of a major histocompatibility complex
(MHC) class II restricted T-cell response by antigen-presenting cells.
Therefore, selective inhibition of this enzyme may be useful in modulating class
II restricted T-cell responses in immune-related disorders such as rheumatoid
arthritis, multiple sclerosis and extrinsic asthma. The three-dimensional
structure at 2.2 A resolution of the active-site Cys25-->Ser mutant presented
here in an unliganded state provides further insight useful for the design of
selective enzyme inhibitors.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 2.
Figure 2 Superposition of the active-site residues of mutant
cathepsin S (in red) and cathepsin K (in yellow). The
hydrogen-bonding network for the mutant enzyme is shown. The
catalytic triad (with the Ser25 mutation) is shown on the right,
with three water molecules in the centre and Gln19 and Trp186 to
the left. Hydrogen bonds are shown as dashed lines. The observed
network may provide a mechanism for correct catalytic residue
side-chain orientation prior to substrate hydrolysis. Also shown
is the final maximum-likelihood-weighted electron-density map
(2F[o] - F[c]), contoured at 1 above
the mean. This figure shows convincingly that the constellation
of the active-site residues is essentially unchanged in the
mutant.
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from the IUCr:
Acta Crystallogr D Biol Crystallogr
(2002,
58,
451-455)
copyright 2002.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Mihelic,
A.Dobersek,
G.Guncar,
and
D.Turk
(2008).
Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
|
| |
J Biol Chem, 283,
14453-14460.
|
 |
|
|
|
|
 |
G.Kaulmann,
G.J.Palm,
K.Schilling,
R.Hilgenfeld,
and
B.Wiederanders
(2006).
The crystal structure of a Cys25 -> Ala mutant of human procathepsin S elucidates enzyme-prosequence interactions.
|
| |
Protein Sci, 15,
2619-2629.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Rossi,
Q.Deveraux,
B.Turk,
and
A.Sali
(2004).
Comprehensive search for cysteine cathepsins in the human genome.
|
| |
Biol Chem, 385,
363-372.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|